Last Updated: November 9, 2026

Details for Patent: 9,867,949

« Back to Dashboard


Which drugs does patent 9,867,949 protect, and when does it expire?

Patent 9,867,949 protects OTREXUP and is included in one NDA.

This patent has nine patent family members in five countries.

Summary for Patent: 9,867,949
Title:Injector safety device
Abstract:A safety member for use with an injection device is disclosed. The safety member includes a blocking ring extending into a housing of the injection device in blocking association with a latch member associated with a trigger mechanism of the injector, in which the blocking ring blocks movement of a portion of the trigger mechanism into a firing position. The safety member further includes a manipulable portion disposed outside the housing and configured for hand-manipulation by a user to remove the safety member from the housing to unblock the firing mechanism to enable firing of the injector.
Inventor(s):Julius C. Sund, Eric Lagman, Peter Hoeft, Paul R. Lesch, Jr., Thomas E. Kramer
Assignee: Antares Pharma Inc
Application Number:US14/339,068
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

Scope and Claims Analysis for US Patent 9,867,949: Medicament Injector with Trigger-Latch Friction Retention and Guard-Actuated Safety Lockout

US 9,867,949 is directed to a disposable, single-use medicament injector platform architecture that links (i) a guard that retracts between protecting and actuating positions, (ii) a safety member that blocks guard motion into the actuating position, and (iii) a firing mechanism where a trigger is retained relative to a latch/ram via a defined frictional force. The independent claim centers on a quantitative force relationship: the trigger firing force is about 2.5 lbf greater than the retaining frictional force between the trigger and the latch/latch engagement interface. Dependent claims then narrow to specific guard locking/safety-member retention mechanisms (blocking member through housing openings, snap-fit removal, cap snap-fit) and specific latch-ram geometry (projection/indentation, flexible arm). The result is an injector claim set with medium structural breadth but meaningful limitations around the safety interlock and the engineered force differential used to control discharge initiation.


What does US 9,867,949 claim cover in a medicament injector?

Short answer: It claims an injector with a housing, medicament container and plunger/ram firing system, and an actuatable guard that can only move the trigger into a firing position when a safety member allows it. The key novelty is the quantified frictional retaining relationship that makes the trigger require a higher first force to move into firing than the retaining frictional force between trigger and latch.

Core elements in Claim 1 (independent claim)

Claim 1 recites a combination of structural and functional relationships:

  1. Injector body and medicament chamber

    • Housing.
    • Container portion disposed within the housing defining a fluid chamber containing medicament.
    • Plunger moveably disposed in the chamber.
    • Ram included in the firing mechanism.
  2. Firing mechanism with latch and trigger

    • Latch moveably disposed within housing engaging a portion of the ram.
    • Trigger moveably disposed within housing between:
      • Ready position: latch held in engagement with ram by the trigger.
      • Firing position: latch released to permit ram movement.
  3. Safety member as a mechanical lockout

    • Safety member positionable relative to housing to restrict trigger movement from ready to firing.
    • Safety member operates by preventing guard movement from protecting to actuating position.
    • Guard extends distally of the housing and is retractable between protecting and actuating positions.
    • Retraction of guard to actuating position causes trigger to move into firing position, except the safety member prevents that transition.
  4. Quantified force relationship

    • Trigger moveable ready to firing by a first force amount.
    • A frictional relationship exists between trigger and latch creating a retaining force in a second amount.
    • The claim specifies: first amount is greater than second amount by about 2.5 lbs of force.

Technical meaning of the 2.5 lbf differential

This is not just a general “higher force” concept. It imposes an engineering constraint: the actuation force needed to overcome trigger-to-latch retention must exceed the frictional retaining force by roughly 2.5 lbf. In practice, this is designed to ensure:

  • the trigger does not inadvertently overcome latch retention during handling;
  • the user-actuation (or guard-driven actuation) does overcome retention once the safety interlock permits firing.

Because it’s written as “about 2.5 lbs,” claim construction will likely treat it as a toleranced quantitative relationship rather than an exact Newton/gram conversion.


How do Claims 2–6 narrow the safety-member and latch/ram mechanics?

What does Claim 2 add?

  • Safety member includes a blocking member that abuts a portion of the trigger.
  • Housing has an opening; blocking member is configured to interact with the trigger through that opening.

What does Claim 3 add?

  • Blocking member is retained within the housing opening by a snap fit.
  • Blocking member is user-removable to permit trigger movement into firing.

This creates a defined removable safety feature with a specific retention mechanism (snap-fit).

What does Claims 4–5 add?

These recite a latch-ram engagement geometry:

  • Latch includes a flexible arm and a projection.
  • Ram includes an indentation.
  • Projection receivable within indentation.
  • When projection is held in indentation in the ready state, latch restricts ram movement.
  • When trigger moves into firing, the projection/indentation disengage, permitting axially relative ram movement.

This portion reads like a typical snap-latch / flexure latch architecture with a projection-based stop and a corresponding recess.

What does Claim 6 add?

  • Adds needle positional relationships relative to the guard in protecting vs retracted positions:
    • Distal end of guard positioned distally of needle tip in protecting.
    • Distal end positioned proximally of needle tip in retracted.

That tightens the safety/guard alignment and shielding function.


How do Claims 7–10 define the safety member structure and guard return logic?

Claim 7

  • Safety member includes:
    • blocking member through housing opening into connection with body portion disposed outside housing.
  • Adds relative positioning and an internal end that abuts guard.

Claim 8

  • Adds axial arrangement:
    • Guard proximal end axially remote from trigger distal end when guard is in guarding position.
    • Blocking member disposed axially between guard proximal end and trigger distal end.

Claim 9

  • Adds a sleeve affixed in housing retaining container.
  • Adds a locking element slidably associated with sleeve:
    • First position: guard retractable into actuating position.
    • Second position: locking element fixes relationship to sleeve and blocks guard into actuating position.

Claim 10

  • Adds a spring biasing guard toward protecting position.
  • Adds logic coupling:
    • After guard retracts and then returns to protecting, the return motion moves locking element into the second position.
    • Retraction engages guard with locking element.

This ties the motion cycle to a lockout state change, making the injector behavior stateful across the injection cycle.


How do Claims 11–14 limit guard/cap snap-fit structure and safety tab insertion?

Claims 11–12 (cap over guard)

  • Cap covers open end of guard and surrounds guard.
  • Cap abuts housing and restricts cap/guard retraction into actuating position.
  • Guard includes flange; cap includes projection achieving snap-fit between guard and cap.

Claim 13

  • Ram extends axially from the plunger.

Claim 14 (tab through opening)

  • Housing has an opening.
  • Safety member includes body portion with tab extending distally along outside of housing.
  • Tab has projection fitting within opening and blocking guard movement.

This is another alternate safety member geometry: external tab/projection that engages an opening to prevent guard actuation.


Claims 15–16: what is claimed about ram-plunger coupling?

  • Claim 15: ram coupled to plunger.
  • Claim 16: ram affixed to plunger.

These are broad coupling definitions and do not add substantial narrowing versus Claim 13’s axial configuration.


What does the dependent claim set in the “Claim 17” architecture broaden, and what does it add?

Claim 17 is another independent claim. It retains the core combination of:

  • injector housing and medicament container/plunger,
  • ram,
  • latch(es),
  • trigger with ready and firing positions,
  • safety member restricting trigger into firing,
  • and a guard retracting to actuating position causing trigger to firing (via guard motion), but it introduces additional framing:

Key additions in Claim 17

  • The firing mechanism includes:
    • at least one latch moveably disposed and latching connection to ram.
    • an inner housing.
  • The at least one latch extends from a proximal end of the inner housing.
  • Axial movement of trigger in proximate direction disengages the latching connection.

This is a different mechanistic emphasis:

  • the trigger disengages the latch by axial proximal movement relative to the inner housing and latch projection geometry.

Claim 18–19: blocking member snap-fit through opening

Same safety-member construction concept:

  • blocking member end disposed within housing abutting portion of trigger,
  • blocking member extends through housing opening and attaches to body portion outside housing,
  • blocking member retained by snap fit, removable by user to permit firing.

Claim 20: repeats the 2.5 lbf relationship but with third force variable

  • First amount: trigger to move into firing.
  • Second amount: retaining force from friction between trigger and latch.
  • Third amount: safety force provided by safety member.
  • The claim still specifies: first amount is greater than second amount by about 2.5 lbs.

This version clarifies that the safety member imposes its own “safety force” yet the quantitative friction differential remains controlling.

Claim 21–22: flexible arm projection into ram indentation

Same geometry as Claim 4–5, but generalized to “at least one latch.”

Claim 23–24: guard retracts and needle tip shielding

  • Guard retracting from protecting to actuating causes portion of guard to move trigger into firing.
  • Needle tip positioned relative to distal guard end in protecting vs retracted states.

Claims 25–26: safety member body portion outside and axial blocking location

Matches Claim 7–8 pattern in the Claim 17 architecture.

Claims 27–28: sleeve/locking element and spring state change

Matches Claim 9–10 pattern.

Claim 29: cap with snap-fit restriction

Matches Claim 11–12 pattern.

Claim 30: slideable trigger with latching portion passing beyond latch

This adds a different trigger mechanics concept:

  • ram urged toward distal end by spring energy source,
  • trigger has latching portion abutting at least one latch,
  • trigger slideable inside an outer housing,
  • when trigger slid approximately to injecting position, latching portion slides beyond latch portion it contacts.

This is a distinct latch release mechanism based on trigger translation beyond latch engagement.

Claim 31: safety member tab with projection in opening

Matches Claim 14.

Claim 32

  • Ram extends axially from plunger (as in Claim 13).

How broad is US 9,867,949 across design-around axes?

The claim set has several potential “design-around” hinges. Competitors can try to avoid infringement by altering:

  1. The quantified friction differential

    • The “first amount greater than second amount by about 2.5 lbs” is a strong constraint.
    • A design that changes friction method (e.g., detents, positive stops, electromagnetic locks, or different tolerance regime without a measurable frictional retaining force meeting that specific differential) may be harder to capture, depending on doctrine of equivalents.
  2. The specific safety interlock mechanism

    • Independent claim 1 requires a safety member that restricts movement of trigger by preventing guard movement from protecting to actuating positions.
    • Dependent claims include multiple alternates:
      • blocking member through housing opening with snap fit removal,
      • cap with snap-fit projection abutting housing,
      • tab/projection through opening.
    • A design that uses electronic sensing, a different physical lockout path not keyed to guarding-to-actuating motion could reduce overlap.
  3. Guard-to-trigger causal link

    • Claim 1: retraction of guard causes trigger to move into firing position, but safety member blocks that movement.
    • Claim 17: similarly guards interact, but Claim 17 emphasizes “proximate direction axial movement” disengaging the latch.
  4. Latch/ram engagement geometry

    • Multiple claims include flexible arm projection into indentation (projection/indentation disengagement).
    • A design that uses different latch geometry or uses purely rotational latch behavior could avoid those dependent claim features.
  5. Outer housing vs inner housing relationships

    • Claim 17 introduces an inner housing and latch extending from proximal end of inner housing.
    • Designs without a comparable inner housing/latch extension architecture may fall outside that version.

Patent landscape: what other US injector patents are likely to overlap with this claim scope?

Without the patent’s bibliographic record, assignee, inventor list, and related prosecution history, a comprehensive cross-patent mapping cannot be completed to litigation-grade standards. This response therefore limits scope to claim-driven landscape axes and identifies the closest technical “families” that commonly create contention in needle-protection and trigger-latch injector systems:

Likely overlapping technology clusters

  1. Needle guard retractable interlock systems

    • Claims similar to “guard distal end relative to needle tip” and “guard protecting to actuating positions.”
  2. User-removable safety locks

    • Snap-fit removable blocking members, caps that block retraction until removed.
  3. Trigger-latch release mechanisms

    • Flexure latch with projection/recess (indentation) and trigger that overcomes holding force through friction, detent, or cam action.
  4. Quantitative actuation-force tuning

    • Less common to see an explicit “about 2.5 lbs” differential in injector patents. Where present, it often marks the specific inventive contribution and becomes a focal point in validity and infringement analyses.

Where disputes typically concentrate

  • Infringement: whether the accused injector has the same safety path (guard-to-trigger) and whether it includes a frictional retaining relationship with a comparable first-vs-second force differential.
  • Validity: whether the quantified force relationship is disclosed in earlier injector designs, and whether it is a mere result-effective-determinative range optimization over known frictional retention systems.

Litigation and Orange Book status

US 9,867,949 is a medical device style patent (injector mechanics). Such patents are frequently asserted alongside drug-device combination products, but Orange Book status is not determinative of device patent enforceability. A complete status check requires the associated NDA/BLA or the specific drug-device combination record, which is not provided here.


Claim-by-claim “infringement anchor” matrix for 9,867,949

Claim Infringement anchor elements (must all be present) Key design-around pressure points
1 Guard protecting→actuating causes trigger ready→firing; safety member blocks guard motion; latch holds ram; frictional relationship between trigger and latch; first vs second force differential about 2.5 lbf Eliminate or change quantified force differential; replace safety lock path not tied to guard motion; avoid frictional retaining relationship formulation
2 Housing opening; safety blocking member abuts trigger Remove opening/abutting configuration; different blocking interface
3 Blocking member retained by snap fit, removable by user Use different retention mechanism; permanent safety member
4 Flexible arm latch; projection; ram indentation; projection held in indentation in ready state Use different latch geometry; replace projection/recess engagement
5 Disengagement when trigger moves into firing permits ram axial movement relative to latch Different disengagement actuation
6 Needle tip relative to distal guard end in protecting vs retracted positions Change guard geometry/coverage timing
7 Blocking member through opening attaching to body outside housing; abut guard portion Different safety-member structure
8 Axial placement of guard proximal end, trigger distal end, and blocking member Reconfigure axial order
9 Sleeve + locking element slidably associated; locking element blocks guard into actuating position in second state Remove locking element/sleeve linkage
10 Spring biases guard to protecting; return motion moves locking element to second state Different spring/return logic
11 Cap covers open end of guard and restricts retraction by abutting housing Replace cap interlock
12 Guard flange and cap projection snap-fit Replace snap-fit connection
13 Ram extends axially from plunger Change mechanical alignment (hard for some architectures)
14 Safety tab/projection fits within opening blocks guard movement Replace tab/opening blocking
15–16 Ram coupled/affixed to plunger Minor narrowing only
17 Inner housing; at least one latch; trigger ready→firing releases latch; latch disengaged by axial proximal trigger movement; safety member restricts trigger into firing Avoid inner-housing/latch extension; change trigger release direction/mechanics
18–19 Blocking member through opening, snap fit removal Same as claims 2–3
20 Adds safety force third amount but preserves 2.5 lbf first>second differential Avoid defined friction retention differential
21–22 Flexible arm + projection + indentation structure Same as claims 4–5
23–24 Guard retract causes trigger move; needle/guard positional relationship Same as claims 6
25–26 Blocking member through opening to external body portion; axial blocking between guard and trigger Same as claims 7–8
27–28 Sleeve locking element and spring-driven state change Same as claims 9–10
29 Cap with flange snap-fit restriction Same as claims 11–12
30 Trigger slideable inside outer housing; latching portion slides beyond latch at injecting position Change trigger translation release sequence
31 Safety tab/projection through housing opening Same as claim 14
32 Ram extends axially from plunger Same as claim 13

What is the patent estate strength for an injector like this?

From a claim-scope perspective, strength concentrates in:

  • the mechanical interlock chain (guard motion linked to trigger firing, with safety member blocking the chain);
  • the quantitative friction retention differential (2.5 lbf);
  • the presence of multiple redundant dependent claim pathways that mirror common product implementations (blocking member with snap fit, cap with snap fit, tab projection through opening, sleeve/locking element with spring return).

Weakness in breadth comes from:

  • explicit mechanical relationships (guard-to-trigger causality, safety member blocking guard protecting-to-actuating motion);
  • the force differential limitation in the independent claim(s);
  • multiple dependent claims requiring specific geometric features (projection/indentation, flexible arm).

A competitor looking to invalidate by obviousness would focus on whether earlier injector designs taught:

  • frictional trigger retention relative to a latch,
  • user-removable safety blocking the guard-to-trigger firing pathway,
  • and a specific tunable force differential in the cited range.

A competitor looking to avoid infringement would target:

  • the quantified force relationship,
  • the friction retaining mechanism itself,
  • or safety interlock logic not dependent on preventing guard motion into an actuating position.

Key Takeaways

  • US 9,867,949 is centered on an injector mechanical safety system where a retractable distal guard controls trigger movement into firing, and a safety member blocks the guard’s protecting-to-actuating transition.
  • The primary technical differentiator is a quantified relationship: trigger firing force exceeds trigger-to-latch frictional retaining force by about 2.5 lbf.
  • Dependent claims lock in common implementation variants: snap-fit removable blocking members, cap-based snap-fit restrictions, tab/projection engagement through housing openings, and sleeve/locking-element state change driven by spring-biased guard return.
  • Validity and infringement risk will concentrate on (i) the guard-trigger-safety-member causal chain and (ii) whether the accused system uses a comparable frictional retaining interface with a comparable force differential.
  • Claim 17 extends coverage through an inner housing/latch extension and trigger axial proximal disengagement emphasis, plus an alternate sliding trigger latching release concept.

FAQs

  1. How does the “about 2.5 lbs” friction differential affect infringement for injector triggers?
    It forces comparison of the accused design’s measured trigger force versus the retaining frictional force at the trigger-latch interface, not just qualitative “higher” actuation.

  2. What design changes most directly avoid the safety-member blocking limitation in US 9,867,949?
    Changing the safety interlock so it does not block guard movement from protecting to actuating, or removing the guard-to-trigger causal linkage.

  3. Do snap-fit removable safety blocks increase litigation risk for competing auto-injectors?
    Yes, because they map to multiple dependent claim embodiments and can satisfy structural feature matching.

  4. Which injector components are most likely to be asserted as “latch” and “ram” equivalents?
    The structural element that holds back the driven plunger/ram release in ready state and disengages on trigger actuation is the typical latch/holding component; equivalence analysis will hinge on whether it functions and interfaces the same way.

  5. How does the projection/indentation flexible-arm latch geometry limit claim coverage?
    Those dependent claims require that specific flexure and complementary recess engagement for the holding and disengagement phases.


References

  1. User-provided claim text for US Patent 9,867,949 (claims 1–32).

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 9,867,949

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cosette OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-005 Nov 7, 2014 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Cosette OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-001 Oct 11, 2013 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
Cosette OTREXUP methotrexate SOLUTION;SUBCUTANEOUS 204824-006 Mar 24, 2016 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.